Sun Pharma Announces the Availability of Cosibelimab-ipdl for Advanced Cutaneous Squamous Cell Carcinoma

On January 16, 2026, Sun Pharmaceutical Industries announced that UNLOXCYT™ (cosibelimab-ipdl) is now available in the US for health care professionals to prescribe for adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

For more information, read the Sun Pharmaceutical Industries press release.

Posted on 1/16/2026